About this trial

This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

Eligibility criteria

Qualifiers

None

Disqualifiers

Children (age<18)

Pregnant females

Developmentally delayed subjects

Subjects unable to provide informed consent

Trial design

Treatments tested in this trial

  • Swept-Source (SS) OCT Angiography
  • Spectral-Domain (SD) OCT Angiography
  • Fundus Imaging
  • Axial Length Measurement Device

Treatment groups

1,050 Participants
are divided into 4 treatment groups

Locations

1
Wilmer Eye Institute21287, BaltimoreMaryland, United States

Sponsors and collaborators

Johns Hopkins University

Lead sponsor

National Eye Institute (NEI)

Collaborator